Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health vector-borne testing Coverage Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Testing for Vector-Borne Infections

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and reimbursement guidance for laboratory testing used to diagnose vector-borne infections (e.g., babesiosis, relapsing fevers, chikungunya, dengue, Zika, WNV, malaria, rickettsial diseases) for Oscar Health members and providers submitting claims.

    Policy Summary
    PayerOscar Health
    PolicyTesting for Vector-Borne Infections
    Policy CodePolicy N/A
    Change TypeTechnical update — no material clinical changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure documentation of specimen type and timing and submit accurate clinical documentation to support medical necessity and potential prior authorization requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~16diseases referenced
    10/01/2026effective date
    1,205RMSF cases (2023)
    84.2%BinaxNOW sensitivity
    30+listed CPT/HCPCS codes

    Coverage Criteria for Vector-Borne Infection Testing

    Covered when ALL of the following are met (by disease-specific entries)

    Covered when ALL of the following are met (by disease-specific entries):

    Babesiosis: For individuals suspected of having babesiosis: Giemsa- or Wright-stained blood smear, nucleic acid amplification testing (NAAT)/PCR, or IgG/IgM indirect immunofluorescence antibody (IFA) assay with initial and confirmatory testing at least two weeks apart MEETS CRITERIA.

    chunk 5

    Relapsing fevers (Borrelia spp.): For suspected relapsing fever: HTRF (serologic assays for Borrelia antibodies) or NAAT for Borrelia miyamotoi (HTRF); peripheral blood smear microscopy or NAAT for Borrelia recurrentis (LBRF); dark-field microscopy, Wright/Giemsa smear, NAAT for Borrelia spp., or serologic assays for STRF/TBRF MEET CRITERIA.

    chunk 5

    Borrelia culture: Culture testing for Borrelia DOES NOT MEET CRITERIA.

    chunk 5

    Policy Summary
    PayerOscar Health
    PolicyTesting for Vector-Borne Infections
    Policy CodePolicy N/A
    Change TypeTechnical update — no material clinical changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionEnsure documentation of specimen type and timing and submit accurate clinical documentation to support medical necessity and potential prior authorization requirements.
    SourceLink
    On This Page
    Coverage Criteria for Vector-Borne Infection TestingRelevant CPT/HCPCS and Code NotesProvider Requirements, Authorization, and DocumentationBackground on Vector-Borne Diseases and DiagnosticsDefinitions and TerminologyPolicy Publication and Revision History
    Chikungunya: For suspected chikungunya: viral culture, NAAT on blood, or IFA IgM testing during acute and convalescent phases MEET CRITERIA.

    chunk 5

    Colorado tick fever (CTF): For suspected CTF: NAAT testing or IFA for CTF-specific IgM antibodies MEET CRITERIA.

    chunk 5

    Dengue virus (DENV): For suspected dengue: NAAT (RT-PCR), IgM antibody capture ELISA (MAC-ELISA), NS1 ELISA, and confirmatory plaque reduction neutralization test (PRNT) MEET CRITERIA when used per clinical indication.

    chunk 6

    Dengue not covered tests: IgG ELISA or hemagglutination testing for DENV DOES NOT MEET CRITERIA.

    chunk 6

    Ehrlichiosis/Anaplasmosis: For suspected ehrlichiosis or anaplasmosis: NAAT (whole blood), IFA for IgG, or microscopy for detection of intraleukocytic morulae MEET CRITERIA.

    chunk 7

    Ehrlichiosis/Anaplasmosis not covered tests: IFA IgM assays or standard blood culture for ehrlichiosis/anaplasmosis DOES NOT MEET CRITERIA.

    chunk 7

    Malaria diagnosis: For suspected malaria: rapid immunochromatographic diagnostic test (RDT) or smear microscopy to diagnose malaria, determine Plasmodium species, identify life-cycle stage, and quantify parasitemia MEET CRITERIA; microscopy may be repeated up to three times within three days if initial microscopy is negative and suspicion remains.max 3 repeats within 3 days if initial microscopy negative

    chunk 7

    Malaria species confirmation: NAAT/PCR to confirm Plasmodium species MEETS CRITERIA.

    chunk 7

    Plasmodium serology not covered: IFA for Plasmodium antibodies DOES NOT MEET CRITERIA for acute diagnosis.

    chunk 7

    Rickettsial disease: For suspected rickettsial disease (e.g., RMSF): IFA IgG assay on paired acute and convalescent sera (initial and confirmatory testing a minimum of two weeks apart) MEETS CRITERIA.paired sera >=2 weeks apart

    chunk 7

    Rickettsial not covered tests: Standard blood culture, NAAT of blood, or IFA IgM for rickettsial disease DOES NOT MEET CRITERIA.

    chunk 7

    West Nile virus (WNV): For suspected WNV: IFA/IgM or IgG testing in serum or CSF with confirmatory PRNT MEETS CRITERIA; nucleic acid detection (NAAT/PCR) MEETS CRITERIA in immunocompromised individuals.

    chunk 7

    WNV NAAT in immunocompetent not covered: NAAT for WNV in immunocompetent individuals DOES NOT MEET CRITERIA.

    chunk 8

    Yellow fever virus (YFV): For suspected YFV: NAAT or serologic assays for IgM/IgG plus confirmatory PRNT MEET CRITERIA.

    chunk 8

    Zika virus NAAT indications: NAAT for Zika MEETS CRITERIA for: symptomatic pregnant individuals up to 12 weeks after symptom onset with relevant exposure; symptomatic non-pregnant individuals in areas with an active CDC Zika Travel Health Notice when symptoms began within the last 7 days.<=12 weeks for symptomatic pregnant; <=7 days for symptomatic non-pregnant in travel-notice areas

    chunk 8

    Zika confirmatory testing: Zika NAAT and IgM testing plus confirmatory PRNT MEET CRITERIA for symptomatic pregnant individuals up to 12 weeks after symptom onset with exposure, pregnant individuals with fetal ultrasound findings consistent with congenital Zika, infants born to individuals who tested positive during pregnancy, infants with signs of congenital Zika and maternal exposure, and symptomatic non-pregnant individuals in travel-notice areas when symptoms presented more than 7 days prior.<=12 weeks for symptomatic pregnant; >7 days for symptomatic non-pregnant in travel-notice areas

    chunks 8,9

    Zika not covered: NAAT and/or IgM testing for Zika in non-pregnant individuals who have not traveled outside the U.S. and its territories DOES NOT MEET CRITERIA.

    chunk 9

    Asymptomatic testing not covered: Testing for babesiosis, chikungunya, CTF, DENV, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, TBRF, WNV, YFV, or Zika during a general exam in asymptomatic individuals without abnormal findings DOES NOT MEET CRITERIA.asymptomatic without abnormal findings

    chunk 9

    Testing guidance by pathogen

    Testing guidance by pathogen:

    Rickettsial testing: When rickettsial infection is suspected, obtain skin biopsy for immunologic detection or PCR prior to antibiotic therapy when possible; IFA serology is standard reference but is often unreliable during the first ~5 days of illness and IgG is more specific than IgM due to cross-reactivity. PCR on tissue has higher specificity than whole blood PCR.serology typically unreliable <5 days

    chunks 20,21,44

    Ehrlichiosis/Anaplasmosis testing: Use NAAT (PCR) on whole blood during the first week of illness as primary diagnostic test; peripheral blood smear to detect intraleukocytic morulae and IFA serology are alternatives/adjuncts; culture is rarely useful clinically.incubation 1-2 weeks; PCR within first week

    chunks 31,63,73

    Borrelia (relapsing fever) testing: For relapsing fever, perform blood smear microscopy during febrile episodes and NAAT on blood/CSF/tissue; serologic seroconversion supports diagnosis; GlpQ antibody assays can help distinguish relapsing fever Borrelia from B. burgdorferi.fever bouts 3-12 days

    chunks 5,63,64

    Babesiosis testing: Preferred diagnostics for babesiosis are blood smear microscopy (Giemsa preferred) for direct identification and PCR/NAAT for Babesia DNA; serology is adjunctive and not ideal for acute diagnosis because antibodies persist after recovery.incubation 1-4 weeks post-tick

    chunks 24,37,72

    Malaria testing: Use microscopy (thick and thin blood smears) as primary diagnostic method; RDTs may be used when microscopy is unavailable but have lower sensitivity and cannot quantify parasitemia; PCR/NAAT is more sensitive at low parasitemia and useful for species confirmation or when differential includes Babesia.PCR detection window variable; microscopy ideally within 24 hours

    chunks 26,31,51,52,36,37

    Arbovirus testing: For arboviruses: use NAAT/RT-PCR or antigen detection early in illness (first week) for viruses such as dengue and chikungunya; serologic testing (IgM, neutralization assays) is useful after the first week but cross-reactivity among flaviviruses is common and PRNT is recommended for confirmation when needed; PCR/viral detection more useful in immunocompromised or atypical cases (e.g., WNV).NAAT/NS1 typically <=7 days after symptom onset

    chunks 27,55,56,58,57,76

    CDC-aligned diagnostic criteria and recommendations

    CDC-aligned diagnostic criteria and recommendations:

    Rickettsial diseases (e.g., RMSF): Perform IFA IgG testing on paired acute and convalescent serum (2–4 weeks apart) and demonstrate a >=4-fold rise in antibody titer for confirmation; PCR of whole blood may be used early but has low sensitivity except in severe disease; PCR or IHC/culture may be performed on skin biopsy or post-mortem tissue at specialized labs.4-fold rise; paired sera 2-4 weeks apart

    chunks 44,45

    Babesiosis: Confirm by identification of intraerythrocytic Babesia on Giemsa/Wright smear OR detection of Babesia spp. DNA in whole blood by NAAT/PCR within 60 days of illness onset OR a four-fold change in IgG titer in paired sera; request manual smear review if suspected.<=60 days for NAAT; four-fold rise for serology

    chunk 50

    Malaria: Microscopy (blood smear) is the CDC gold standard for diagnosis, species identification, staging, and quantification; RDTs may be used where microscopy is unavailable but should be confirmed by microscopy; PCR is more sensitive and useful for species confirmation and detecting mixed infections but is not timely for initial management.microscopy results within 24 hours ideally

    chunks 51,52

    Relapsing fevers (STRF/HTRF/LBRF): Direct visualization of spirochetes in peripheral blood smear during febrile episodes is generally adequate; PCR is more sensitive and preferred during asymptomatic periods; serology is most sensitive when specimens collected >=14 days after symptom onset; interpret results in clinical and epidemiologic context due to cross-reactivity.>=14 days for serology sensitivity

    chunk 63

    Chikungunya and WNV: Chikungunya: viral detection (culture or NAAT) in early illness and IgM/neutralizing antibodies later. WNV: IgM assays are front-line screening tests but antibody-positive screening tests should be evaluated by PRNT to confirm and differentiate flavivirus infections; PCR primarily for immunocompromised or prior flavivirus exposures.N/A

    chunks 55,56,57

    Zika and dengue testing (CDC-based recommendations)

    Zika and dengue testing (CDC-based recommendations):

    Pregnant, asymptomatic patients who lived in/traveled to US/territories: Routine Zika testing is not recommended when no confirmed cases have been detected in U.S. territories since 2018.NA

    chunk 60

    Pregnant patients with travel to area with active CDC Zika Travel Health Notice: Perform dengue and Zika NAAT and IgM on serum and Zika NAAT on urine; consider NAAT up to 12 weeks after travel; if Zika NAAT positive with negative IgM, repeat NAAT on newly extracted RNA; confirm IgM-positive specimens with PRNTs as indicated.<=12 weeks after travel

    chunks 60,61

    Symptomatic pregnant patients: Collect specimens as soon as possible up to 12 weeks after symptom onset; perform NAAT and IgM per CDC guidance and repeat NAAT on newly extracted RNA if initial NAAT positive and IgM negative; confirm IgM-positive results with PRNTs.<=12 weeks after symptoms

    chunk 60

    Symptomatic non-pregnant patients with travel/living in area with transmission: Perform dengue and Zika NAATs on serum ≤7 days after symptom onset; if NAAT-negative, perform IgM testing and confirm positive IgM with PRNTs when definitive diagnosis is needed.<=7 days for NAAT

    chunks 58,60

    Arbovirus testing (WNV, YFV, chikungunya)

    Arbovirus testing (WNV, YFV, chikungunya):

    Chikungunya suspected within first week of symptoms: Perform viral culture or NAAT on serum during the first week due to high viremia; IgM antibodies develop toward the end of the first week and may persist for months; be aware of potential cross-reactivity with other alphaviruses.first week for NAAT/viral culture

    chunk 75,57

    West Nile virus suspected: Use IgM assay for frontline screening; antibody-positive screening results should be evaluated by PRNT to confirm and differentiate flaviviruses; viral isolation/RT-PCR useful in immunocompromised or early viremia but generally not recommended for neuroinvasive disease in immunocompetent patients due to absent viremia.NA

    chunks 55,56,57

    Yellow fever suspected: Perform virus isolation or NAAT as early as possible; serology (IgM/IgG) can be used but confirm with PRNT because of cross-reactivity; YF is nationally notifiable and public health authorities should be notified.early in illness for NAAT/isolation

    chunk 57

    Tickborne and parasitic infections (IDSA/ASM, AAP guidance)

    Tickborne and parasitic infections (IDSA/ASM, AAP guidance):

    Relapsing fever borreliae: Primary testing: Wright's, Giemsa, or Diff-Quik stains of peripheral thin and thick blood smears; NAAT and serology are additional tests; optimum specimens include blood and bone marrow.NA

    chunk 63

    Lyme disease: Early localized disease (erythema migrans): testing not routinely recommended; for suspected disseminated or late disease, follow two-tier testing with EIA screening and supplemental IgM/IgG immunoblots or EIA only if initial EIA is positive or equivocal; avoid performing immunoblot unless initial EIA positive/equivocal.paired acute/convalescent sera when optimal

    chunks 64,65

    Anaplasma/Ehrlichia: Primary test for acute infection is NAAT/PCR within the first week; Wright/Giemsa peripheral smear can identify morulae during first week; serology (paired acute/convalescent IFA) can demonstrate a fourfold rise in IgG for confirmation; note that doxycycline reduces PCR sensitivity.PCR within first week

    chunks 65,66,73

    Rickettsia (RMSF): Confirmatory testing: IFA for Rickettsia rickettsii antigen with IgG preferred over IgM; confirmation requires a fourfold or greater increase in antigen-specific IgG between acute (1-2 weeks) and convalescent (2-4 weeks later) sera.acute and convalescent sera 2-4 weeks apart; fourfold rise

    chunks 73,74

    Babesiosis: Primary testing: Giemsa- or Wright-stained thin and thick blood smears (Giemsa preferred) with manual (nonautomated) review explicitly requested; NAAT is a primary test for acute infection in some settings; serology is adjunctive and not recommended for acute diagnosis alone.repeat smears as needed; consider reference lab confirmation

    chunks 72,73,74

    This policy lists multiple pathogen-specific explicit exclusions. Examples include: culture testing for Borrelia (relapsing fever) which DOES NOT MEET CRITERIA (culture is rarely useful clinically and is specifically excluded) and the use of IgG ELISA or hemagglutination testing for dengue which DOES NOT MEET CRITERIA. For ehrlichiosis/anaplasmosis, an IFA IgM assay and standard blood culture DO NOT MEET CRITERIA. For Plasmodium, IFA for Plasmodium antibodies DOES NOT MEET CRITERIA. For rickettsial diseases, standard blood culture, NAAT, or IFA IgM are listed as tests that DO NOT MEET CRITERIA. West Nile virus NAAT is specifically not covered for immunocompetent individuals. Finally, Zika NAAT and/or IgM testing in symptomatic non‑pregnant individuals who have not traveled outside the U.S. and its territories DOES NOT MEET CRITERIA, and routine testing during a general exam in asymptomatic individuals without abnormal findings for the enumerated vector‑borne infections DOES NOT MEET CRITERIA.

    No additional explicit coverage exclusions are stated in the cited segments of this excerpt. The document instead provides descriptions of testing types (culture, IFA, darkfield microscopy, blood smear, NAAT) and discusses relative strengths and limitations of methods without adding further exclusions beyond the disease‑specific exclusions detailed elsewhere in the policy.

    Rapid diagnostic tests (RDTs) for malaria can be used where microscopy is not immediately available, but an RDT alone is insufficient for full diagnostic workup: RDTs cannot reliably distinguish all Plasmodium species, cannot quantify parasitemia, and may be less sensitive than expert microscopy or PCR. Positive RDT results should be corroborated by microscopy and, when species confirmation is needed, by NAAT/PCR.

    CDC‑aligned guidance reflected in the policy indicates that routine testing for dengue or Zika viruses is not recommended for asymptomatic non‑pregnant patients. For pregnant patients and other higher‑risk scenarios the policy outlines time‑dependent NAAT/IgM algorithms, but for asymptomatic non‑pregnant individuals routine screening is not advised.

    The policy highlights limitations of serologic testing: antibody assays (IgM and IgG) can persist for months to years after infection and therefore a positive IgM or IgG alone may not indicate current or acute infection. The text cites evidence that IgM serology can produce false positives (for example in RMSF and other spotted‑fever group rickettsiae) and that serologic confirmation often requires paired acute and convalescent sera demonstrating a fourfold rise in IgG titer to establish recent infection.

    This portion of the document contains reference listings and does not itself state coverage criteria or exclusions; refer to the policy body for applicable testing indications and limitations and to the cited references for supporting evidence.

    Testing performed as part of a routine general examination in asymptomatic individuals without abnormal findings for babesiosis, chikungunya, Colorado tick fever, dengue, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, tick‑borne relapsing fever, West Nile virus, yellow fever, or Zika virus DOES NOT MEET CRITERIA and is considered not medically necessary.

    Limitations of certain tests are emphasized: IgM serology may yield false positives (example: RMSF and other SFG rickettsiae) and serologic results can reflect past exposure rather than acute disease. The policy therefore advises caution in interpreting isolated IgM or IgG results without appropriate timing, clinical correlation, or confirmatory testing (e.g., paired sera with fourfold rise or PRNT for flaviviruses).

    The document notes specific performance limitations for some assays: the BinaxNOW malaria RDT—though FDA‑approved for laboratory use—has reported lower sensitivity (~84.2%) in non‑endemic settings and may misclassify Plasmodium falciparum as non‑falciparum. In general, RDTs are less capable than microscopy or PCR for species discrimination and parasitemia quantification.

    Reiterating CDC guidance in the policy, Zika and dengue testing algorithms depend on patient status and timing; specifically, testing for dengue or Zika viruses is not recommended for asymptomatic non‑pregnant patients. For pregnant or symptomatic patients the policy follows time windows for NAAT and IgM testing consistent with CDC recommendations.

    The policy notes that laboratory‑developed tests (LDTs) are not FDA‑cleared or approved but are permitted under CLIA when appropriately validated by the performing laboratory; LDTs are regulated as high‑complexity tests by CMS and may be used clinically when validated.

    Within the cited excerpts there are no additional explicit 'not medically necessary' declarations beyond those already stated for asymptomatic general exam screening and the disease‑specific exclusions listed in the policy. The document predominantly provides clinical guidance on appropriate testing modalities, specimen types, and timing rather than broad NMN statements in these chunks.

    Relevant CPT/HCPCS and Code Notes

    Testing method descriptors (no billing codes provided)mixed
    No codes listed
    No explicit billing codes in this sectionmixed
    No codes listed
    Listed antibody and serologic CPT codesCPT
    86280Hemagglutination inhibition test (HAI).
    86382Neutralization test, viral.
    86619Antibody; Borrelia (relapsing fever).
    86666Antibody; Ehrlichia.
    86750Antibody; Plasmodium (malaria).
    86753Antibody; protozoa, not elsewhere specified.
    86757Antibody; Rickettsia.
    86788Antibody; West Nile virus, IgM.
    86789Antibody; West Nile virus.
    86790Antibody; virus, not elsewhere specified.
    Mixed molecular, microscopy, culture, and proprietary test codesCPT
    86794Antibody; Zika virus, IgM.
    87040Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates.
    87164Dark field examination, any source; includes specimen collection.
    87166Dark field examination, any source; without collection.
    87478Infectious agent detection by nucleic acid (DNA or RNA); Ehrlichia chaffeensis, amplified probe technique.
    87798Amplified probe technique, each organism.
    87899Observation; not otherwise specified (listed proprietary TBRF immunoblots).
    inv-24: hematocrit rise for dengue hemorrhagic fever
    Hematocrit threshold≥ 20 percent rise in hematocrit above baseline (evidence of hemoconcentration in dengue hemorrhagic fever)
    Associated findingsPleural effusion or ascites may accompany hemoconcentration in DHF
    Clinical contextUsed to identify plasma leakage characteristic of dengue hemorrhagic fever
    inv-25: NAAT/PCR testing window (typical ≤7 days after symptom onset)
    Typical detection windowNAAT/RT-PCR detection is preferred in acute infection and is typically most useful ≤7 days after symptom onset
    Pathogens referencedApplies to many arboviruses (dengue, chikungunya) and early acute tickborne infections (e.g., Anaplasma/Ehrlichia PCR within first week)
    Specimen preferenceSerum (and urine for Zika NAAT per WHO) recommended for early molecular testing

    Provider Requirements, Authorization, and Documentation

    Prior Authorization

    Authorization and medical necessity required

    Services must meet authorization and medical‑necessity guidelines for the procedure, diagnosis, and the member’s state of residence; coverage does not guarantee reimbursement. Providers are responsible for submitting accurate documentation and correct coding; failure to follow coding/billing guidelines or to provide accurate/incomplete documentation may lead to claim denial or recoupment.

    • Coverage determinations depend on individual benefit coverage at time of request (see Applicable State and Federal Regulations).
    • Follow standard coding guidelines (CPT, ICD‑10, CMS NCCI, etc.).
    Prior Authorization

    Prior authorization — none stated in excerpt

    The policy text does not state any specific prior‑authorization program or codes that always require prior authorization in this excerpt. Verify payer‑specific prior authorization rules before ordering specialized assays.

    • No explicit universal prior authorization requirement is listed in the policy text.
    • Confirm payer or network prior‑auth requirements for individual members.
    Prior Authorization

    Prior authorization not specified — follow CDC recommendations for testing

    The document does not specify uniform prior‑authorization requirements for the tests described; clinicians should follow CDC guidance for test selection and specimen timing and verify member benefits and payer rules when ordering tests.

    • Testing selection and timing guidance aligned to CDC recommendations (e.g., NAAT/NS1 ≤7 days for dengue).
    • Confirm member eligibility and payer rules before testing.
    Documentation Required

    Validated laboratory testing required

    Use only laboratory tests that have undergone independent comprehensive assessment of quality, safety, and performance, and perform testing in appropriately equipped laboratories by trained staff.

    • WHO: “Only laboratory tests that have undergone independent, comprehensive assessment of quality, safety and performance should be used.”
    • Perform testing in appropriately equipped labs by trained personnel.
    Billing Rule

    Potential prior authorization for listed test codes — verify payer rules

    Certain molecular, serologic, antigen, and specialized assays are enumerated with CPT/HCPCS codes in the policy; providers should verify whether payer prior‑authorization is required for any listed CPT/HCPCS codes before ordering.

    • Examples of listed codes include 86794 (Zika IgM), 87478 (Ehrlichia NAAT), 87798 (amplified probe), and proprietary TBRF immunoblots (87899).
    • Confirm payer prior‑auth requirements per member and contract.
    Prior Authorization

    Prior authorization not specified in reference/publication sections

    The reference and publication‑history sections in the excerpt do not list any additional prior‑authorization requirements.

    • Publication history shows governance approval on 06/16/2026.
    • No further prior‑auth triggers are specified in the referenced sections.
    Note

    (No requirement specified in source text.)

    Step Therapy

    Step therapy / testing sequence — no formal step‑therapy

    No formal step‑therapy rules are described in the policy; clinical guidance recommends preferred diagnostic approaches (e.g., NAAT/PCR early in illness, serology or paired sera for confirmation, blood smear for malaria/babesia) but these are not framed as enforced step‑therapy.

    • Example: PCR/NAAT is preferred within the first week for Anaplasma/Ehrlichia; serology (paired acute and convalescent) is required for rickettsial confirmation.
    • Two‑tier Lyme algorithm is clinical guidance (see Lyme testing sequence) rather than a payer step‑therapy requirement.
    Note

    (No requirement specified in source text.)

    Step Therapy

    Lyme testing sequence — two‑tier testing required

    For suspected Lyme disease, follow two‑tier testing: perform an EIA (or other screening EIA) and only perform supplemental IgM/IgG immunoblot or supplemental EIAs if the initial EIA is positive or equivocal; do not perform immunoblot unless the screening EIA is positive or equivocal.

    • Two‑tier testing is the recommended sequence for early disseminated/late Lyme disease (acute/convalescent sera optimal).
    Step Therapy

    Step therapy — none specified

    The policy explicitly states there are no step‑therapy requirements specified in this section.

    • Clinical guidance on diagnostic choices is provided but not framed as an enforced step‑therapy policy.
    Step Therapy

    Step therapy — none specified in these chunks

    Clinical guidance in the cited chunks likewise indicates no step‑therapy mandates for the tests discussed.

    • Providers should follow clinical algorithms and CDC/IDSA guidance rather than an insurer‑imposed step therapy sequence for these diagnostics.
    Documentation Required

    Documentation and applicability — providers must document services accurately

    Providers are responsible for submitting accurate documentation of services performed; application of the policy criteria depends on the individual’s benefit coverage and the facts of the case.

    • Ensure documentation supports medical necessity for the ordered test and ties specimen timing/type to clinical presentation.
    • Coverage determinations depend on the member’s benefit coverage at time of request.
    Documentation Required

    Specimen and testing modality notes — document specimen type and modality

    The policy text describes testing modalities and specimen types (serum, whole blood, tissue, CSF, urine, FFPE) relevant to test selection but does not prescribe specific submission or billing forms; document the specimen type used and the testing modality selected.

    • Types of testing discussed include NAAT, IFA, blood smear, culture, darkfield microscopy, and serology.
    • No explicit specimen submission rules are provided in these chunks.
    Documentation Required

    Specimen timing and type must be documented

    Document the timing of specimen collection and the specimen type used (e.g., acute vs convalescent serum, whole blood, CSF, urine) because interpretation and confirmation depend on specimen timing and type (for example, NAAT/NS1 for dengue is most useful ≤7 days after symptom onset).

    • CDC: paired sera and timing affect confirmatory interpretation (e.g., babesiosis and rickettsial diseases).
    • NAAT/NS1 for dengue and many arboviruses is most sensitive ≤7 days after symptom onset.
    Documentation Required

    Specimen and timing documentation — record specimen type and timing

    Document specimen type and timing relative to symptom onset (for example, serum, CSF, urine; collect dengue/Zika NAAT on serum ≤7 days after symptom onset; consider urine for Zika NAAT).

    • WHO recommends whole blood/serum/plasma routine testing for arboviruses and urine for Zika NAAT.
    • Record symptom onset date and specimen collection date to support test interpretation.
    Documentation Required

    Paired serology documentation — collect and document paired sera and fourfold rise

    Paired acute and convalescent sera (collected ~2–4 weeks apart) are recommended for serologic confirmation for several infections (e.g., anaplasmosis/ehrlichiosis, RMSF, babesiosis) and documentation of a four‑fold rise in IgG titer should be provided when used for confirmation.

    • CDC/AA P: a fourfold rise in antibody titer between acute and convalescent sera confirms recent infection.
    • Document dates of both specimen collections and titer results on the claim/record.
    Documentation Required

    Blood smear testing documentation — request manual smear review and document repeats

    For suspected babesiosis or malaria, explicitly request manual review of Giemsa‑ or Wright‑stained blood smears and, if clinical suspicion persists after a negative initial smear, repeat smears every 12–24 hours for up to 72 hours as indicated; document that manual (nonautomated) review was requested.

    • AA P: manual (nonautomated) review of blood smears should be requested explicitly for babesiosis.
    • If initial malaria smears are negative but suspicion persists, repeat every 12–24 hours up to 72 hours.
    Note

    Publication history note — governance date recorded (no extra provider documentation requirements)

    Publication history shows governance approval on 06/16/2026; the publication history section does not impose additional provider documentation requirements in the excerpt.

    • Policy origination/governance date: 06/16/2026.
    • No further provider documentation rules are contained in the publication history chunk.
    Denial Risk

    Denial risk for improper coding or documentation

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is inaccurate or incomplete; ensure coding and clinical documentation justify the test ordered.

    • Follow industry coding guidelines (CPT, ICD‑10, CMS NCCI, etc.).
    • Support medical necessity with clinical notes, specimen type, collection timing, and lab results when submitting claims.
    Denial Risk

    (No explicit provider‑facing authorization or billing denial triggers are present in these chunks of the excerpt.)

    • The excerpt contains clinical/testing guidance and code lists but does not define specific denial triggers beyond general coding/documentation compliance.
    Denial Risk

    Paired sera required for confirmatory serology — missing paired sera risks non‑confirmation

    Failure to obtain paired acute and convalescent sera and to demonstrate a fourfold rise in antibody titer when required (e.g., rickettsial diseases, babesiosis) may prevent laboratory confirmation and could affect diagnostic interpretation and coverage decisions.

    • CDC and AAP: a fourfold rise in IgG between acute and convalescent sera is required to confirm several tickborne infections.
    • Document both specimen dates and titer changes when using serology for confirmation.
    Denial Risk

    Flavivirus confirmation — confirm IgM/IgG screening positives with PRNT or reference testing

    Initial antibody‑positive screening tests for flaviviruses (e.g., WNV, dengue, Zika) should be confirmed with a more specific test such as plaque reduction neutralization test (PRNT); failure to confirm antibody‑positive screening may result in inadequate diagnostic confirmation.

    • CDC: antibody screening tests are considered screening only; PRNT is recommended to differentiate flavivirus infections and confirm IgM‑positive specimens.
    • Specimens should be tested against other arboviruses active in the region or travel area.
    Denial Risk

    Time‑sensitive PCR — perform Anaplasma/Ehrlichia PCR within first week

    Perform PCR/NAAT for Anaplasma and Ehrlichia within the first week of illness because doxycycline therapy rapidly decreases PCR sensitivity; delayed testing after antibiotics may yield false‑negative PCR results.

    • AAP/IDSA guidance: PCR sensitivity declines rapidly after initiation of doxycycline; collect whole blood for NAAT within first week.
    • If PCR is negative but clinical suspicion remains, rely on paired serology for diagnosis.
    Denial Risk

    Government policy precedence — follow applicable LCD/NCD/state Medicaid rules

    If there is a conflict between this policy and an applicable government policy (for example, Medicare LCD/NCD or state Medicaid), the government policy will take precedence and will be used to make coverage determinations.

    • Consult CMS LCD/NCD or state Medicaid rules when member coverage is governed by those programs.
    Note

    (No explicit authorization or denial triggers are present in these document chunks beyond those already noted.)

    • The publication history and references do not add provider‑facing denial triggers in the excerpt.

    Background on Vector-Borne Diseases and Diagnostics

    Arthropod vectors including mosquitoes, ticks, fleas, and mites transmit a range of pathogens—bacteria, protozoa, and viruses—that cause illnesses such as Zika, West Nile virus, chikungunya, dengue, yellow fever, malaria, babesiosis, rickettsial diseases, ehrlichiosis/anaplasmosis, and Borrelia-associated relapsing fevers. Diagnostic approaches vary by agent and clinical context and include microscopy (blood smears, dark-field), culture (rarely useful for many agents), NAAT (PCR/RT-PCR), serologic assays (IFA, ELISA, MAC-ELISA), and confirmatory plaque-reduction neutralization testing (PRNT) for flaviviruses.

    Definitions and Terminology

    inv-53: NAAT definition
    DefinitionNucleic acid amplification testing (NAAT): molecular methods such as PCR, qPCR, or RT-PCR used to detect pathogen nucleic acid; preferred for early detection of viral RNA
    Typical usePreferred for detecting viral RNA early in acute infection (time-limited detection window)
    ExamplesTechniques include PCR, qPCR, and RT-PCR; used for dengue, Zika, chikungunya, and other arboviruses
    inv-54: IFA definition
    DefinitionIndirect immunofluorescence antibody assay (IFA): serologic test that detects antigen-specific IgG or IgM using fluorescent-labeled antibodies
    Role in diagnosisStandard reference serologic test for many tickborne rickettsial infections; requires paired acute and convalescent sera with ≥4-fold rise for confirmation
    Timing limitationInsensitive during the first week of acute infection; IgG is more specific than IgM
    inv-55: Rocky Mountain spotted fever (RMSF) definition
    DefinitionRocky Mountain spotted fever (RMSF): a spotted fever rickettsiosis caused by Rickettsia rickettsii transmitted primarily by Dermacentor ticks
    Clinical featuresPresents with fever, headache, characteristic rash (in ~88–90%); can be fatal if untreated
    Diagnostic notesDiagnosis via skin biopsy (PCR/IHC), serology (IFA with paired sera demonstrating ≥4-fold rise), or specialized PCR assays; serology often negative in first 5 days
    inv-56: Ehrlichiosis and Anaplasmosis definitions
    DefinitionEhrlichiosis and Anaplasmosis: tickborne infections caused by Ehrlichia spp. and Anaplasma phagocytophilum, presenting with fever, leukopenia, thrombocytopenia
    DiagnosticsDiagnosed commonly by IFA serology, PCR (NAAT) on whole blood in the first week, or identification of intraleukocytic morulae on peripheral smear
    Timing notePCR is most sensitive within the first week; doxycycline treatment rapidly decreases PCR sensitivity
    inv-57: Babesiosis definition
    DefinitionBabesiosis: protozoal infection (primarily Babesia microti in the U.S.) causing fever and hemolysis
    Preferred diagnosticsBlood smear microscopy (Giemsa/Wright) for intraerythrocytic parasites and PCR for Babesia DNA; serology is adjunctive and not ideal for acute diagnosis
    Clinical concernsImmunocompromised patients may relapse; manual smear review and reference lab confirmation should be requested when suspected
    inv-58: Arboviral infections definition
    DefinitionArboviral infections: viruses transmitted by arthropods (e.g., West Nile, dengue, Zika, yellow fever, chikungunya); cause variable clinical syndromes
    Diagnostic approachMolecular detection (NAAT/RT-PCR) or antigen detection preferred early; serology (IgM ELISA/MAC-ELISA) used later but cross-reactivity is common and PRNT may be required for confirmation
    Specimen/timing notesSpecimen selection and interpretation depend on timing since symptom onset (e.g., NAAT useful ≤7 days for many arboviruses; urine NAAT for Zika per WHO guidance)
    inv-59: IFA (serologic reference) definition
    DefinitionIFA (serologic reference): indirect immunofluorescence antibody assay used as the reference serologic test for many tickborne rickettsial infections
    Confirmation requirementRequires paired acute and convalescent sera (usually 2–4 weeks apart) and a minimum fourfold rise in IgG titer for confirmed diagnosis
    LimitationsInsensitive in the first week of illness; IgG preferred over IgM due to greater specificity
    inv-60: RDT definition for malaria
    DefinitionRapid diagnostic test (RDT) for malaria: immunochromatographic antigen-detection test that provides results in minutes and is useful when microscopy is unavailable
    LimitationsRDTs cannot always distinguish Plasmodium species, may be less sensitive than expert microscopy or PCR, cannot quantify parasitemia, and may remain positive after clearance
    Use caseUseful as an alternative when timely microscopy is not available; positive RDT should be confirmed by microscopy and, if needed, NAAT for species confirmation
    inv-61: PRNT definition
    DefinitionPlaque reduction neutralization test (PRNT): reference-standard serologic assay that measures virus-neutralizing antibodies and differentiates flavivirus infections
    RoleRecommended to confirm antibody-positive screening tests (e.g., WNV, dengue, Zika) because of cross-reactivity among flaviviruses
    AvailabilityComplex assay available at select public health and reference laboratories (CDC/selected labs)
    inv-62: NAAT definition (RT-PCR preferred early in infection)
    Definition and preferenceNAAT (e.g., RT-PCR) — preferred early in infection for detection of viral RNA; detection window is limited and depends on pathogen and specimen
    Examples of applicationPreferred for dengue detection within 0–7 days of symptoms; RT-PCR is the definitive test for Zika RNA in symptomatic patients; used for early chikungunya detection
    Specimen considerationsSerum is preferred for many arboviruses; WHO recommends whole blood/serum/plasma and urine for Zika NAAT as applicable
    inv-63: Paired sera / seroconversion definition
    DefinitionPaired sera / seroconversion: collection of acute and convalescent serum specimens (typically 2–4 weeks apart) demonstrating a fourfold or greater rise in IgG titer to confirm recent infection
    Use casesRecommended for confirmation of rickettsial diseases, babesiosis (when using serology), anaplasmosis/ehrlichiosis, and some arboviral infections when cross-reactivity exists
    Documentation requirementProvide timing of specimen collection and demonstration of fourfold rise when used for diagnostic confirmation
    inv-64: Laboratory-developed test (LDT) definition
    DefinitionLaboratory-developed test (LDT): a diagnostic test developed and validated in-house by a laboratory and regulated under CLIA as high-complexity testing (not FDA-cleared/approved)
    Regulatory noteLDTs are not FDA-approved/cleared for clinical use but are permitted under CLIA when validated by the performing laboratory
    Use cautionEnsure LDTs have undergone appropriate validation and are performed in appropriately equipped laboratories
    inv-65: CDC/WHO guidance reference definition
    DefinitionCDC/WHO guidance: authoritative public health diagnostic and laboratory testing recommendations from the CDC and World Health Organization for vector-borne infections
    ScopeProvides disease-specific testing algorithms, specimen recommendations, timing considerations, and confirmatory testing guidance (e.g., PRNT for flaviviruses)
    Reference practicePolicy aligns testing and confirmation criteria with CDC/WHO guidance; providers should follow applicable CDC/WHO recommendations and cite them in documentation

    Policy Publication and Revision History